ReviewCalcium channel regulation in vascular smooth muscle cells: Synergistic effects of statins and calcium channel blockers
Section snippets
Introduction and background
The Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA) recently demonstrated the large beneficial effects of adding a lipid lowering agent (atorvastatin) to blood pressure (BP) lowering therapy in hypertensive patients not deemed dyslipidaemic [1]. The study showed a 35% reduction in the primary endpoint of fatal coronary heart disease (CHD) and non-fatal myocardial infarction for the atorvastatin versus placebo treated groups. Two BP lowering regimens were used in
Actions of statins
Statins are the first line of treatment in the therapy of dyslipidaemia and have well documented favourable effects on the stability of established plaques [7]. These vasculoprotective actions are thought to be due to a number of mechanisms, some LDL-dependent and some LDL-independent. Many of the ‘pleiotropic’ actions of statins have been attributed to beneficial effects on endothelial function (reviewed in [8]), while possible actions on VSMC have been relatively neglected. Although the
Calcium channel blockers: Mode of action
Calcium channel blockers (CCB) are a chemically heterogeneous class of drugs consisting of dihydropyridines (DHPs), phenylalkylamines and benzothiazepines. All CCB share a common mechanism of action—the inhibition of Ca2+ influx through L-type calcium channels. This channel constitutes the dominant Ca2+ influx route in contractile VSMC and inhibition of L-type calcium channels accounts for the antihypertensive and vasodilator properties of CCB. Other Ca2+ influx routes exist in VSMC which are
Clinical trials involving calcium channel blockers
Observations in man are even more inconsistent than in animal models. In three studies using coronary angiography, the Montreal Heart Institute trial [35], the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT) [36] and The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) [37] treatment with CCB did not influence the overall rate of coronary lesion progression or minimal coronary artery diameter, although CCB-treated patients had less
Molecular mechanisms
Recently we proposed a molecular mechanism to account for these observations [50]. We showed that transition of human VSMC from a relatively differentiated (growth arrested or contractile phenotype) to a less differentiated state (synthetic phenotype) following serum stimulation was associated with loss of effect of CCB on both intracellular Ca2+ signalling and chemotaxis in response to platelet-derived growth factor (an important chemotactic agent and mitogen for VSMC). These observations
The hypothesis
Together these observations suggest a hypothesis that incorporates the loss of efficacy of CCBs on advanced plaques and provides a basis for the co-operative action of CCBs with statins. As VSMCs dedifferentiate, CCB-sensitive L-type calcium channels are functionally downregulated. The effect is independent of context and may occur in response to vascular injury, development, remodelling, plaque formation, or in cell culture. This in turn imposes a ceiling on CCB efficacy such that efficacy
Acknowledgement
This work was supported by grants from the British Heart Foundation and the Foundation for Circulatory Health. The authors acknowledge support from the NIHR Biomedical Research Centre Funding Scheme.
The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology [57].
References (57)
- et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Lancet
(2003) - et al.
The nonlipid effects of statins on endothelial function
Trends Cardiovasc Med
(2006) - et al.
Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
Biochim Biophys Acta
(1997) - et al.
Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture
Atheroscler
(2000) - et al.
Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase
Athero
(1993) - et al.
Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization
J Biol Chem
(2001) T-type Ca2+ channels in vascular smooth muscle: multiple functions
Cell Calcium
(2006)Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence
Atheroscler
(2002)- et al.
Mechanisms controlling gene expression by nuclear calcium signals
Cell Calcium
(1998) - et al.
Calcium and the replication of human vascular smooth muscle cells: studies on the activation and translocation of extracellular signal regulated kinase (ERK) and cyclin D1 expression
Eur J Pharmacol
(2005)
Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size
Atheroscler
Mechanism of antiatherogenic action of calcium antagonists
Atheroscler
Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators
Lancet
Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty
Am Heart J
Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty
J Am Coll Cardiol
Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES)
J Am Coll Cardiol
Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial
J Am Coll Cardiol
Ethical authorship and publishing
Int J Cardiol
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial
Eur Heart J
Inflammation, atherosclerosis, and coronary artery disease
N Engl J Med
Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study
JAMA
Molecular regulation of vascular smooth muscle cell differentiation in development and disease
Physiol Rev
Fibrous cap formation or destruction—the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation
Cardiovasc Res
Mechanisms of plaque stabilization with statins
Am J Cardiol
Rho GTPases and signaling networks
Genes Dev
Rho GTPases, statins, and nitric oxide
Circ Res
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and over expression of eNOS
Naunyn Schmiedebergs Arch Pharmacol
Regression of chronic hypoxic pulmonary hypertension by simvastatin
Am J Physiol Lung Cell Mol Physiol
Cited by (34)
Dose-related neuropathic and anti-neuropathic effects of simvastatin in vincristine-induced neuropathic pain in rats
2015, Food and Chemical ToxicologyCitation Excerpt :They are used clinically to treat patients with cardiovascular disease like atherosclerosis, stroke and peripheral arterial disease due to their cholesterol lowering effect (Ali and Alexander, 2007; Golomb et al., 2008). However, statins exhibit umpteen pleiotropic cholesterol independent effects including anti-oxidants by reducing superoxide formation (Uekawa et al., 2014), anti-inflammatory by reducing macrophage migration (Ma et al., 2014), anti-microbial effect in staphylococcus blood infections (López-Cortés et al., 2013), modulation of the neurotrophic levels (Wu et al., 2008) and up-regulation of L-type Ca2+ channel affecting smooth muscle contraction (Clunn et al., 2010). Due to these multiple activities, preclinical studies have suggested the potential beneficial role of statins in a number of other diseased states like cancer (Khurana et al., 2007; Kong et al., 2014; Mondul et al., 2011), arthritis (Gottschalk et al., 2014), chronic obstructive pulmonary disease (Criner et al., 2014), Alzheimer's disease and Parkinson's disease (Barone et al., 2014; Wolozin et al., 2007) and chronic kidney disease (Dasari et al., 2014).
Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells
2014, Journal of Biological ChemistryCitation Excerpt :Our results demonstrating that nimodipine potently suppresses simvastatin-induced toxicity (Fig. 6C) suggest that simvastatin increases the activity of L-type calcium channels (Fig. 7, dashed arrow). This leads to mitochondrial calcium influx and increased release of proapoptotic factors such as cytochrome c. Interestingly, it has been hypothesized by others that statins can directly increase the expression of L-type calcium channels in vascular smooth muscle cells (66). In our experimental paradigm, simvastatin did not alter total protein levels of L- or T-type channels.
Statins: Do they aggravate or ameliorate neuropathic pain?
2014, Journal of PainAmlodipine in the current management of hypertension
2023, Journal of Clinical Hypertension